研究单位：[1]Cancer Institute and Hospital, Chinese Academy of Medical Sciences[2]Hebei Medical University Fourth Hospital[3]Affiliated Hospital of Hebei University[4]Beijing Army General Hospital[5]Beijing Hospital[6]Peking University First Hospital[7]Tianjin Medical University Cancer Institute and Hospital[8]Henan Cancer Hospital[9]The Affiliated Hospital of Inner Mongolia Medical University[10]The First Affiliated Hospital with Nanjing Medical University[11]Fujian Cancer Hospital
This prospective, non-randomized phase II study aims to compare radiotherapy and concurrent nimotuzumab with concurrent chemoradiotherapy to obtain a non-inferior pCR rate and pathological lymph node metastases rate in premise of lower toxicities in locally advanced esophageal cancer.
